Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
- PMID:33844998
- PMCID: PMC8040539
- DOI: 10.1016/S2213-2600(21)00171-5
Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
Erratum in
- Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00171-5.[No authors listed][No authors listed]Lancet Respir Med. 2021 Jun;9(6):e55. doi: 10.1016/S2213-2600(21)00186-7. Epub 2021 Apr 14.Lancet Respir Med. 2021.PMID:33864734Free PMC article.No abstract available.
Conflict of interest statement
AA and RF are the leading investigators of a multicentre, randomised clinical trial supported by AstraZeneca, which is currently exploring the effects of inhaled budesonide in hospitalised patients with COVID-19 pneumonia (NCT04355637).
Comment on
- Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell REK, Bafadhel M.Ramakrishnan S, et al.Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.Lancet Respir Med. 2021.PMID:33844996Free PMC article.Clinical Trial.
References
- Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28–33. - PubMed
- Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonar disease (GOLD) 2021.www.goldcopd.org
- Global strategy for asthma management and prevention (GINA) 2020 update. 2020.https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-... - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

